Preliminary studies reported a promising result of apatinib treatment for patients with advanced rectal cancer, advanced non-small-cell lung cancer, and advanced cervical cancer, in which their serum CEA levels decreased significantly, the survival time prolonged, with good safety profile [18–21]. Here, CEACAM5 is linked to rectal cancer.